Erasca Share Price Today
(NASDAQ: ERAS)

Name: Erasca Share Price Today (NASDAQ: ERAS) - Erasca Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Erasca share price is $1.39 & ₹118.79 as on 26 Apr 2025, 2.30 'hrs' IST

$1.39

▲

-0.01

(-0.71%)

Live

View live Erasca share price in Dollar and Rupees. Guide to invest in Erasca stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Erasca, along with analyst recommendations, forecasts, and comprehensive financials.

Erasca share price movements

Today's Low: $1.34
Today's High: $1.42
$1.39
3.96%
Downside
Day's Volatility :5.99%
Upside
2.11%
52 Weeks Low: $1.01
52 Weeks High: $3.45
$1.39
27.34%
Downside
52 Weeks Volatility :70.72%
Upside
59.71%

Erasca (ERAS) Returns

Period	Erasca Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-28.21%	-4.8%	0.0%
6 Months	-46.97%	-7.5%	0.0%
1 Year	-25.53%	-1.8%	0.0%
3 Years	-82.84%	2.1%	-9.5%

Erasca (ERAS) Key Statistics

in dollars & INR

Previous Close	$1.4
Open	$1.37
Today's High	$1.42
Today's Low	$1.335
Market Capitalization	$402.2M
Today's Volume	$584.8K
52 Week High	$3.45
52 Week Low	$1.01
Revenue TTM	$0.0
EBITDA	$-148.6M
Earnings Per Share (EPS)	$-0.71
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-43.68%

How to invest in Erasca Stock (ERAS) from India?

It is very easy for Indian residents to invest directly in Erasca from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Erasca stock in both Indian Rupees (INR) and US Dollars (USD). Search for Erasca or ERAS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Erasca or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Erasca shares which would translate to 0.615 fractional shares of Erasca as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Erasca, in just a few clicks!

Returns in Erasca (ERAS) for Indian investors in Rupees

The Erasca stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Erasca investment value today

Current value as on today

₹76,511

Returns

₹23,489

(-23.49%)

Returns from Erasca Stock

₹26,064 (-26.06%)

Dollar Returns

₹2,575 (+2.58%)

Indian investors sentiment towards Erasca (ERAS)

200%

Period: Mar 25, 2025 to Apr 24, 2025. Change in 30 Days versus previous period

Search interest for Erasca Stock from India on INDmoney has increased by 200% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Erasca

T. Rowe Price Investment Management,Inc.
5.90%
VR Adviser, LLC
5.72%
BlackRock Inc
5.56%
Vanguard Group Inc
4.47%
Logos Global Management LP
4.41%
Suvretta Capital Management, LLC
4.35%

Analyst Recommendation on Erasca

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Erasca(by analysts ranked 0 to 5 stars)

Analyst Forecast on Erasca Stock (ERAS)

What analysts predicted

Upside of 277.7%

Target:

$5.25

Current:

$1.39

Insights on Erasca Stock (Ticker Symbol: ERAS)

Price Movement
In the last 7 days, ERAS stock has moved up by 20.7%
ERAS vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 72.4% return, outperforming this stock by 97.9%
ERAS vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.3% return, outperforming this stock by 140.8%

Erasca Technicals Summary

Sell

Neutral

Buy

Erasca is currently in a neutral trading position according to technical analysis indicators.

Erasca (ERAS) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Erasca Inc.	-5.41%	-46.97%	-25.53%	-82.84%	-91.97%
Regeneron Pharmaceuticals, Inc.	-6.31%	-35.72%	-32.66%	-11.12%	9.54%
Beone Medicines Ltd	2.09%	20.37%	72.43%	67.9%	55.25%
Vertex Pharmaceuticals Incorporated	-1.56%	3.09%	23.83%	83.97%	83.41%
Alnylam Pharmaceuticals, Inc.	-9.88%	-14.83%	68.82%	56.52%	70.01%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Erasca Inc.	NA	NA	NA	-0.55	-0.44	-0.21	NA	1.5
Regeneron Pharmaceuticals, Inc.	15.27	15.27	0.94	39.99	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Erasca Inc.	Buy	$402.2M	-91.97%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$64.0B	9.54%	15.27	31.07%
Beone Medicines Ltd	NA	$28.7B	55.25%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.6B	83.41%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.3B	70.01%	NA	-12.37%

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Organization	Erasca
Employees	103
CEO	Dr. Jonathan E. Lim M.D.
Industry	Services

Management People of Erasca

Name	Title
Dr. Jonathan E. Lim M.D.	Co-Founder, Chairman & CEO
Dr. David M. Chacko M.D.	CFO & Chief Business Officer
Mr. Ebun S. Garner Esq., J.D.	General Counsel & Corporate Secretary
Dr. Michael D. Varney Ph.D.	Chairman of Research & Development, Scientific Advisory Board Member and Director
Dr. Nik Chetwyn Ph.D.	Chief Operating Officer
Dr. Lisa Tesvich-Bonora Ph.D.	Chief People Officer
Mr. Brian L. Baker CPA, M.S.	Senior Vice President of Finance
Ms. Chandra D. Lovejoy M.S.	Chief Regulatory Affairs Officer
Dr. Robert Shoemaker Ph.D.	Senior Vice President of Research
Dr. Shannon R. Morris M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in ERAS Stock from India :

What is Erasca share price today?

Erasca share price today stands at $1.39, Open: $1.44 ; Previous Close: $1.40 ; High: $1.42 ; Low: $1.34 ; 52 Week High: $3.45 ; 52 Week Low: $1.01.

The stock opens at $1.44, after a previous close of $1.40. The stock reached a daily high of $1.42 and a low of $1.34, with a 52-week high of $3.45 and a 52-week low of $1.01.

Can Indians buy Erasca shares?

Yes, Indians can invest in the Erasca (ERAS) from India.

With INDmoney, you can buy Erasca at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Erasca at zero transaction cost.

How can I buy Erasca shares from India?

It is very easy to buy Erasca from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Erasca (ERAS) be purchased?

Yes, you can buy fractional shares of Erasca with INDmoney app.

What are the documents required to start investing in Erasca stocks?

To start investing in Erasca, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.